NCT01687790View on ClinicalTrials.gov

The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Breast Abnormalities
Interventions
DEVICE

molecular breast imaging (Discovery)

Trial Locations (1)

15232

Hillman Cancer Center, Pittsburgh

Sponsors

Collaborators (1)

GE Healthcare
All Listed Sponsors
collaborator

GE Healthcare

INDUSTRY

lead

University of Pittsburgh

OTHER

NCT01687790 - The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease | Biotech Hunter | Biotech Hunter